Form 8-K - Current report:
SEC Accession No. 0001193125-26-206382
Filing Date
2026-05-05
Accepted
2026-05-05 16:07:38
Documents
11
Period of Report
2026-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20260505.htm   iXBRL 8-K 56921
2 EX-99.1 trvi-ex99_1.htm EX-99.1 119418
3 GRAPHIC img251553556_0.jpg GRAPHIC 29443
  Complete submission text file 0001193125-26-206382.txt   339355

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20260505.xsd EX-101.SCH 28531
14 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20260505_htm.xml XML 4711
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 26943074
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)